Can a shorter course of radiation tame prostate cancer with fewer side effects?

NCT ID NCT01352429

Ongoing Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests two types of radiation therapy—proton therapy and IMRT—for men with low- to intermediate-risk prostate cancer. The goal is to see if a shorter, more intense radiation schedule (hypofractionation) can improve cancer control while reducing side effects. The study tracks how well patients tolerate treatment and monitors for any short- or long-term urinary or bowel issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (proton therapy or intensity-modulated radiation therapy)
What this could lead to: If successful, this approach could offer a more convenient, shorter course of radiation with fewer side effects for men with prostate cancer.
What could go wrong: This is a mid-stage trial, so the benefits are not yet proven. There is a risk of increased side effects from the shorter radiation schedule.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Show contact details

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Walter Reed National Military Medical Center

Bethesda, Maryland, 20889, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.